Grifols has opened its €90 million bioscience division global operations centre in Ireland, which is expected to generate 140 jobs when it is fully operational in 2016. The company is the world’s third-largest plasma product manufacturer and a pioneer in the research and development of therapeutic alternatives designed to contribute to both scientific and social development. The facility is located at Grange Castle Business Park, Dublin, and will house operating activities including the warehousing of plasma, intermediate and finished product; labelling, packaging and final conditioning of the product; regulatory and quality activities relating to the supply of plasma and plasma derivatives; R&D global management office; administrative and commercial activities among others. The bioscience division generated sales revenue of €2,513 million in 2014, or 75 per cent of the group’s total net revenue. It manufactures plasma proteins and focuses on promoting its therapeutic use. Approximately €90 million has been invested in the new facility in Dublin, that occupies 22,000 m² of an 11-hectare site.  The project is the result of Grifols growth strategy, with a strong emphasis on the internationalisation and globalisation of activities. Grifols generated 93.4 per cent of its sales outside of Spain in 2014, and it has direct commercial presence in 30 countries, while distributing products to a total of 100 countries. “Grifols is a very welcome addition to the thriving life sciences sector in Ireland.  Its decision to establish this important part of its international business in Ireland plays an important role in attracting other investments from the European marketplace, said Martin Shanahan, CEO, IDA Ireland. “This is a breakthrough investment for Ireland in the important blood plasma subsector of biopharmaceuticals.”